(VIANEWS) – IBERSOL,SGPS (IBS.LS), SKUE SPAREBANK (SKUE.OL), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. IBERSOL,SGPS (IBS.LS)
500.5% sales growth and 35.54% return on equity
Ibersol, S.G.P.S., S.A., through its subsidiaries, operates a network of restaurants in Portugal, Spain, and Angola. The company operates restaurants under various brands, including Pizza Hut, Pasta Caffé, Pans & Company, Ribs, FresCo, SantaMaria, Kentucky Fried Chicken, Burger King, O' Kilo, Quiosques, Pizza Móvil, Miit, Taco Bell, Sol, Silva Carvalho Catering e Palace Catering, Travel, coffee counters, and other concessions contract. The company was founded in 1989 and is headquartered in Porto, Portugal. Ibersol, S.G.P.S., S.A. is a subsidiary of ATPS – SGPS, S.A.
Earnings Per Share
As for profitability, IBERSOL,SGPS has a trailing twelve months EPS of €1.98.
PE Ratio
IBERSOL,SGPS has a trailing twelve months price to earnings ratio of 3.37. Meaning, the purchaser of the share is investing €3.37 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.54%.
Moving Average
IBERSOL,SGPS’s value is way higher than its 50-day moving average of €5.94 and way higher than its 200-day moving average of €5.91.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 17, 2022, the estimated forward annual dividend rate is 0.14 and the estimated forward annual dividend yield is 2.15%.
Yearly Top and Bottom Value
IBERSOL,SGPS’s stock is valued at €6.68 at 07:20 EST, higher than its 52-week high of €6.60.
More news about IBERSOL,SGPS.
2. SKUE SPAREBANK (SKUE.OL)
17% sales growth and 9.06% return on equity
Skue Sparebank provides various banking products and services for individual and business in Norway. The company offers operating, tax deduction, capital, client, deposit, and group accounts; business, construction, personal, vehicle, and small loans, as well as mortgage, bank guarantee, overdraft, and leasing services; and home and leisure, car and other vehicles, pet, company and employees, agriculture insurance products. It also provides savings and pension products; and online and mobile banking, bank card, and payment services. The company was formerly known as Nes Prestegjelds Sparebank and changed its name to Skue Sparebank in October 2013. Skue Sparebank was founded in 1842 and is based in Geilo, Norway.
Earnings Per Share
As for profitability, SKUE SPAREBANK has a trailing twelve months EPS of kr82.41.
PE Ratio
SKUE SPAREBANK has a trailing twelve months price to earnings ratio of 2.77. Meaning, the purchaser of the share is investing kr2.77 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.06%.
Volume
Today’s last reported volume for SKUE SPAREBANK is 344 which is 71.4% below its average volume of 1203.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 409.21M for the twelve trailing months.
Moving Average
SKUE SPAREBANK’s worth is below its 50-day moving average of kr232.36 and above its 200-day moving average of kr219.67.
Sales Growth
SKUE SPAREBANK’s sales growth is 20% for the current quarter and 17% for the next.
More news about SKUE SPAREBANK.
3. NAVAMEDIC (NAVA.OL)
9.6% sales growth and 16.31% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr0.45.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 82. Meaning, the purchaser of the share is investing kr82 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.31%.
Moving Average
NAVAMEDIC’s value is under its 50-day moving average of kr38.28 and higher than its 200-day moving average of kr34.03.
Sales Growth
NAVAMEDIC’s sales growth is 72.2% for the ongoing quarter and 9.6% for the next.
Volume
Today’s last reported volume for NAVAMEDIC is 1204 which is 94.67% below its average volume of 22608.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr36.90 at 07:20 EST, way under its 52-week high of kr43.60 and way higher than its 52-week low of kr25.00.
More news about NAVAMEDIC.
